Autolus Therapeutics Provides Business Updates and 2025 Overview

Ongoing commercial launch of AUCATZYL® on track, with 24 treatment centers fully authorized as of January 10th - National Comprehensive Cancer Network® adds AUCATZYL® to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) - Company to provide clinical development program updates, including plans for expansion into autoimmune disease, at April 23rd R&D investor event LONDON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company ...